4DMT Grants 96,000 RSUs to 7 New Employees Under Nasdaq Inducement Rule
Updated
Updated · Yahoo Finance UK · Sep 11
4DMT Grants 96,000 RSUs to 7 New Employees Under Nasdaq Inducement Rule
2 articles · Updated · Yahoo Finance UK · Sep 11
Summary
September 8 grants gave seven new non-executive 4DMT employees a total of 96,000 restricted stock units, the company said Friday.
The awards came from 4DMT's amended 2025 Employment Inducement Award Plan and were approved by the board compensation committee to attract hires under Nasdaq Rule 5635(c)(4).
4DMT is a late-stage biotech whose lead candidate, 4D-150, is in Phase 3 development for wet age-related macular degeneration, with diabetic macular edema as a second indication.
The company also highlighted 4D-710 for cystic fibrosis, underscoring that all of its product candidates remain in clinical or preclinical development and are not yet approved for marketing.
With a massive credit facility secured, are 4DMT's new equity grants signaling an aggressive hiring surge for its critical Phase 3 retinal trials?
Can 96,000 restricted stock units effectively lock in top biotech talent before 4DMT's investigational eye therapy faces the ultimate test of FDA approval?